Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2 Trial of NAV4694 as an Aid in Diagnosing Alzheimer’s Disease
Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2 Trial of NAV4694 as an Aid in Diagnosing Alzheimer’s Disease
Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2 Trial of NAV4694 as an Aid in Diagnosing Alzheimer’s Disease
Submitted by
moderatorj
on September 18, 2012 - 10:57pm
Source:
Yahoo/BusinessWire
News Tags:
Navidea Biopharmaceuticals
enrollment
clinical trials
patients
Alzheimer's disease
Headline:
Navidea Biopharmaceuticals Announces Enrollment of First Subject in Phase 2 Trial of NAV4694 as an Aid in Diagnosing Alzheimer’s Disease
Do Not Allow Advertisers to Use My Personal information
